drugset
drugset / Trial / NCT05909943

Efficacy and Safety of Ruxolitinib in Neuromyelitis Optica Spectrum Disorders

NCT05909943 ↗

Phase 1/2 Withdrawn Tianjin Medical University General Hospital
NaSingle-groupOpen-labelBasic science

Summary

Neuromyelitis Optica Spectrum Disorders (NMOSD) is associated with a pathological humoral immune response against the aquaporin-4(AQP-4) water channel. Rucotinib is an oral inhibitor of JAK1 and JAK2 tyrosine kinases. It may benefit some patients with NMOSD due to the important role of JAK/STAT signaling pathway in the pathogenesis of NMOSD. Clincial trials may be needed to observe its efficacy and safety.

Timeline

Start
2024-06-01
Primary completion
2026-02-01
Completion
2026-08-01

Outcome

Outcome not reported

Stopped: “We are doing a clinical study of Baritinib in Neuromyelitis Optica Spectrum Disorders, similar to this one, so the study was withdrawn.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Ruxolitinib Small molecule 10 mg Oral
Subject Ruxolitinib Small molecule 15 mg Oral

Indications

neuromyelitis optica